BioSpace News Archive

Ocugen, Inc. today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL.

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech.

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.

Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024.

Verona Pharma plc, announces eight posters, including two mini oral symposia, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease will be presented at the American Thoracic Society International Conference 2024.

Ikerian AG and its subsidiary, RetinAI U.S. Inc. a leading developer of software solutions for medical image and data management

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe.

Global health company The Cigna Group reported strong first quarter 2024 results reflecting growth across its diversified portfolio of businesses.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 94,000 shares of KalVista common stock on May 1, 2024 as inducements material to each employee entering into employment with KalVista.